Madrigal Pharmaceuticals, Inc. (BIT:1MDGL)
Italy · Delayed Price · Currency is EUR | Market Cap | 10.13B +42.5% |
| Revenue (ttm) | 1.12B +149.0% |
| Net Income | -284.56M |
| EPS | -12.44 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 457.60 |
| Day's Range | n/a |
| 52-Week Range | 319.00 - 518.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania. [Read more]
Financial Performance
In 2025, Madrigal Pharmaceuticals's revenue was $958.40 million, an increase of 432.05% compared to the previous year's $180.13 million. Losses were -$288.28 million, -38.12% less than in 2024.
Financial numbers in USD Financial StatementsNews
Madrigal Appoints John C. Reed, M.D.
CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc...
Madrigal Pharmaceuticals Transcript: Canaccord Genuity's 46th Annual Growth Conference
Rezdiffra has demonstrated rapid commercial growth, surpassing 50,000 patients and achieving a $1.3 billion run rate, with strong physician support and minimal competitive impact. The pipeline has expanded to ten assets, focusing on combination therapies, and major regulatory milestones are expected to further boost growth and market leadership.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ...
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the Canaccord Genuity 46th Annual Growth Confere...
Madrigal upgraded to Outperform from Peer Perform at Wolfe Research
Wolfe Research upgraded Madrigal Pharmaceuticals (MDGL) to Outperform from Peer Perform with a $605 price target The firm says the shares overcorrected on perception of its stage 4 liver fibrosis…
Madrigal Pharmaceuticals price target lowered to $962 from $964 at Barclays
Barclays analyst Eliana Merle lowered the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $962 from $964 and keeps an Overweight rating on the shares. The firm views the company’s…
Madrigal Pharmaceuticals price target lowered to $543 from $553 at BofA
BofA lowered the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $543 from $553 and keeps a Neutral rating on the shares. The Q2 print “stood out to us less…
Madrigal Pharmaceuticals Earnings Call Transcript: Q2 2026
Rezdiffra delivered $364M in Q2 2026 net sales (up 71% YoY), surpassing 50,000 active patients and nearly $1.3B in trailing 12-month sales, with robust U.S. growth and negligible European contribution. The company advances a broad MASH pipeline and expects continued strong sales and patient growth in 2026.
Madrigal Pharmaceuticals Earnings release: Q2 2026
Madrigal Pharmaceuticals released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Madrigal Pharmaceuticals Slides: Q2 2026
Madrigal Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Madrigal Pharmaceuticals Quarterly report: Q2 2026
Madrigal Pharmaceuticals has published its Q2 2026 quarterly earnings report on July 30, 2026.
Madrigal Pharmaceuticals reports Q2 EPS ($1.99), consensus ($2.23)
Reports Q2 revenue $364.25M, consensus $352.51M. Bill Sibold, Chief Executive Officer of Madrigal, stated: “Madrigal delivered another outstanding quarter driven by exceptional execution and market fu...
Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
CONSHOHOCKEN, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc...
Madrigal Pharmaceuticals price target raised to $587 from $578 at Canaccord
Canaccord raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $587 from $578 and keeps a Buy rating on the shares. The firm updated its model ahead of Q2…
Madrigal Pharmaceuticals initiated with an Overweight at Wells Fargo
Wells Fargo initiated coverage of Madrigal Pharmaceuticals (MDGL) with an Overweight rating and $685 price target The firm sees over $7B in peak sales for Rezdiffra. A survey of doctors…
Madrigal Pharmaceuticals price target raised to $553 from $542 at BofA
BofA raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $553 from $542 and keeps a Neutral rating on the shares. The firm updated its model for recent commentary…
Madrigal Pharmaceuticals price target raised to $739 from $737 at Citizens
Citizens raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $739 from $737 and keeps an Outperform rating on the shares ahead of the Q2 report on July 30.
Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026
CONSHOHOCKEN, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2026 financial results on Thursday, July 30, ...
Madrigal Pharmaceuticals announces three new resmetirom patents
Madrigal Pharmaceuticals (MDGL) announced that the United States Patent and Trademark Office, or USPTO, issued three new resmetirom patents. Bill Sibold, CEO of Madrigal, stated: “Building a robust pa...
Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio
Received two new U.S. Rezdiffra ® (resmetirom) patents in F2/F3; both patents will be listed in the FDA's Orange Book Received new U.S. resmetirom patent directed to a method of administering resmetir...
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
SUZHOU, China and MÖLNDAL, Sweden, July 1, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in c...
Madrigal Pharmaceuticals management to meet with Piper Sandler
Meeting to be held in New York on June 22 hosted by Piper Sandler.
Madrigal Pharmaceuticals price target lowered to $542 from $550 at BofA
BofA lowered the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $542 from $550 and keeps a Neutral rating on the shares. While Rezdiffra’s launch in MASH has impressed, debate…
Madrigal Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Rezdiffra’s launch has driven rapid sales growth and market expansion, with over 42,250 patients treated and strong prescriber adoption. The company is leveraging its first-mover advantage, robust pipeline, and favorable financials to pursue long-term leadership in the growing MASH market.
Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026
CONSHOHOCKEN, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 47th Annual Global Goldman Sachs Health Care...